XML 108 R77.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue from contract with customer (Details)
€ in Millions, $ in Millions
1 Months Ended 12 Months Ended 15 Months Ended
Jul. 01, 2023
CHF (SFr)
Nov. 01, 2022
CHF (SFr)
May 01, 2021
CHF (SFr)
Oct. 30, 2020
USD ($)
Jan. 02, 2018
USD ($)
item
Aug. 31, 2022
CHF (SFr)
Jan. 31, 2018
USD ($)
Dec. 31, 2023
CHF (SFr)
Dec. 31, 2022
CHF (SFr)
Dec. 31, 2021
CHF (SFr)
Dec. 31, 2019
USD ($)
Jul. 31, 2022
CHF (SFr)
Dec. 31, 2004
EUR (€)
Revenue from contract with customer                          
Revenue from contract with customer               SFr 1,612,953 SFr 1,422,438 SFr 2,916,308      
Indivior PLC                          
Revenue from contract with customer                          
Number of distinct material promises and performance obligations | item         2                
Indivior PLC | Rights granted                          
Revenue from contract with customer                          
Revenue from contract with customer | $             $ 5.0            
Indivior PLC | Achievement of pre-specified milestones                          
Revenue from contract with customer                          
Variable consideration allocated to contract | $         $ 330.0                
Indivior PLC | Research                          
Revenue from contract with customer                          
Revenue from contract with customer               1,600,000 1,400,000 2,900,000      
Initial research term         2 years                
Contract funding for research and development costs incurred | $         $ 4.0                
Increment period for extension of research term         12 months                
Number of newly identified compounds selected | item         1                
Additional funding for research and development costs incurred SFr 2,700,000 SFr 950,000 SFr 3,700,000 $ 2.8   SFr 850,000         $ 1.6    
Research funding received                       SFr 2,700,000  
Research funding paid by investor to third parties                       SFr 1,000,000.0  
Research funding to be received 1,100,000                        
Research funding to be paid by investor to third parties SFr 1,600,000                        
Contract asset and trade receivables               100,000 400,000        
Indivior PLC | Research | Indivior PLC                          
Revenue from contract with customer                          
Number of newly identified compounds selected | item         1                
Janssen Pharmaceuticals Inc. | Development                          
Revenue from contract with customer                          
Revenue from contract with customer               SFr 0 SFr 0 SFr 0      
Janssen Pharmaceuticals Inc. | Development | Maximum                          
Revenue from contract with customer                          
Variable consideration allocated to contract | €                         € 109